País: Irlanda
Língua: inglês
Origem: HPRA (Health Products Regulatory Authority)
MEMANTINE HYDROCHLORIDE
Rowex Ltd
N06DX01
MEMANTINE HYDROCHLORIDE
10 Milligram
Film Coated Tablet
Product subject to prescription which may not be renewed (A)
Other anti-dementia drugs
Authorised
2013-07-04
PACKAGE LEAFLET: INFORMATION FOR THE USER MEMANTINE SANDOZ 10 MG FILM-COATED TABLETS Memantine hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Memantine Sandoz is and what it is used for 2. What you need to know before you take Memantine Sandoz 3. How to take Memantine Sandoz 4. Possible side effects 5. How to store Memantine Sandoz 6. Contents of the pack and other information 1. WHAT MEMANTINE SANDOZ IS AND WHAT IT IS USED FOR _ _ HOW DOES MEMANTINE SANDOZ WORK Memantine Sandoz belongs to a group of medicines known as anti-dementia medicines. Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory. Memantine Sandoz belongs to a group of medicines called NMDA-receptor antagonists. Memantine Sandoz acts on these NMDA-receptors improving the transmission of nerve signals and the memory. WHAT IS MEMANTINE SANDOZ USED FOR Memantine Sandoz is used for the treatment of patients with moderate to severe Alzheimer’s disease. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MEMANTINE SANDOZ _ _ DO NOT Leia o documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Memantine Sandoz 10 mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg memantine hydrochloride which is equivalent to 8.31 mg of memantine. Excipient(s) with known effect: each tablet contains 132 mg lactose monohydrate. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet. White film-coated tablet of oval shape (6.1 x 11.6 mm) with a breaking line on both sides. The tablet can be divided into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of patients with moderate to severe Alzheimer's disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Posology Therapy should only be started if a caregiver is available who will regularly monitor the intake of the medicinal product by the patient. Diagnosis should be made according to current guidelines. The tolerance and dosing of memantine should be reassessed on a regular basis, preferably within three months after start of treatment. Thereafter, the clinical benefit of memantine and the patient's tolerance of treatment should be reassessed on a regular basis according to current clinical guidelines. Maintenance treatment can be continued for as long as a therapeutic benefit is favourable and the patient tolerates treatment with memantine. Discontinuation of memantine should be considered when evidence of a therapeutic effect is no longer present or if the patient does not tolerate treatment. _Adults:_ DOSE TITRATION The recommended starting dose is 5 mg per day, which is stepwise increased over the first 4 weeks of treatment reaching the rec Leia o documento completo